Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin destined for the treatment of diabetes.
Located at the Technopark Grabtsevo in the Kaluga region of Russia, the plant is the first and only greenfield facility for manufacturing modern insulin in the county, with environmental targets for CO² emission, water consumption and use of energy, according to the Danish drugmaker.
Around 10 million people in Russia are thought to have diabetes, and Novo says its move will ensure availability of high-quality modern insulin’s to patients.
“I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor, Anatoly Artamonov.
Novo currently also has production sites in Denmark, Brazil, China, France and the US.